Compare VERA & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERA | TARS |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.7B |
| IPO Year | 2021 | 2020 |
| Metric | VERA | TARS |
|---|---|---|
| Price | $35.49 | $62.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | $81.30 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 1.1M | 468.6K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $451,360,000.00 |
| Revenue This Year | N/A | $56.43 |
| Revenue Next Year | $472.48 | $30.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $18.76 | $38.51 |
| 52 Week High | $56.05 | $85.25 |
| Indicator | VERA | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 37.97 | 40.48 |
| Support Level | $22.10 | $61.24 |
| Resistance Level | $42.77 | $76.47 |
| Average True Range (ATR) | 1.83 | 3.27 |
| MACD | -0.34 | 0.09 |
| Stochastic Oscillator | 16.98 | 41.87 |
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.